Compare ALV & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALV | TGTX |
|---|---|---|
| Founded | 1953 | 1993 |
| Country | Sweden | United States |
| Employees | 64100 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 8.5B |
| IPO Year | N/A | 2008 |
| Metric | ALV | TGTX |
|---|---|---|
| Price | $114.11 | $53.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $134.00 | $49.80 |
| AVG Volume (30 Days) | 702.9K | ★ 2.8M |
| Earning Date | 04-17-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | N/A | ★ 0.12 |
| Revenue | N/A | ★ $2,785,000.00 |
| Revenue This Year | $2.10 | $49.08 |
| Revenue Next Year | $3.47 | $26.69 |
| P/E Ratio | ★ $13.10 | $446.04 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $99.16 | $25.37 |
| 52 Week High | $132.17 | $57.38 |
| Indicator | ALV | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.24 | 71.20 |
| Support Level | $99.80 | $28.57 |
| Resistance Level | $123.80 | $57.38 |
| Average True Range (ATR) | 3.20 | 2.40 |
| MACD | -1.13 | 0.15 |
| Stochastic Oscillator | 0.96 | 68.64 |
Autoliv Inc is a developer, manufacturer, and supplier of passive safety systems to the automotive industry with a broad range of product offerings. Its product portfolio includes passive safety systems for commercial vehicles, battery cut-off switches, safety solutions for riders of motorcycles and bikes, airbags (including steering wheels and inflators), seatbelts, etc. Geographically, the group operates in the Americas, Europe, China, and Asia, excluding China, of which the maximum revenue is generated from its business in the Americas.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.